QNTM
FSD Pharma Inc - Class B - Class B (Sub Voting) (QNTM)
Healthcare • NASDAQ • $4.88-2.59%
- Symbol
- QNTM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.88
- Daily Change
- -2.59%
- Market Cap
- $28.87M
- Trailing P/E
- N/A
- Forward P/E
- -0.63
- 52W High
- $38.25
- 52W Low
- $2.07
- Analyst Target
- $12.75
- Dividend Yield
- N/A
- Beta
- N/A
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome…
Company websiteResearch QNTM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.